Privium Fund Management B.V. - PROQR THRAPEUTICS N V ownership

Quarter-by-quarter ownership
Privium Fund Management B.V. ownership history of PROQR THRAPEUTICS N V
ValueSharesWeighting
Q3 2023$6,947,780
-19.8%
5,344,4460.0%2.07%
+13.2%
Q2 2023$8,658,003
-23.9%
5,344,4460.0%1.82%
-52.3%
Q1 2023$11,383,670
-36.8%
5,344,4460.0%3.82%
-44.0%
Q4 2022$18,010,783
+346.0%
5,344,4460.0%6.83%
+365.6%
Q3 2022$4,038,000
-2.8%
5,344,4460.0%1.47%
+6.5%
Q2 2022$4,156,000
-12.4%
5,344,446
+1.9%
1.38%
+31.3%
Q1 2022$4,747,000
-87.8%
5,244,446
+10.0%
1.05%
-86.4%
Q4 2021$38,935,0004,765,6597.72%
Other shareholders
PROQR THRAPEUTICS N V shareholders Q4 2023
NameSharesValueWeighting ↓
M28 Capital Management LP 1,910,600$3,095,1724.09%
Privium Fund Management B.V. 5,344,446$8,658,0031.82%
DAFNA Capital Management LLC 940,582$1,523,7430.42%
Opaleye Management Inc. 653,000$1,057,8600.25%
Ikarian Capital, LLC 472,625$765,6530.12%
EcoR1 Capital, LLC 2,980,016$4,827,6260.12%
Monaco Asset Management SAM 237,517$384,7780.11%
FRANKLIN STREET ADVISORS INC /NC 150,000$2430.02%
ADAGE CAPITAL PARTNERS GP, L.L.C. 3,625,467$5,873,2570.01%
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 189,328$306,7110.01%
View complete list of PROQR THRAPEUTICS N V shareholders